Compositions containing alpha-2-adrenergic agonist components
Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
1 . A therapeutically effective aqueous ophthalmic composition comprising:
a solution containing about 0.1% (w/v) of an alpha 2 adrenergic agonist selected from the group comprising 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, a salt of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, and an ester of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, wherein the composition has a pH of about 7.7.
2 . The composition of claim 1 which comprises about 0.1% (w/v) of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline tartrate.
3 . The composition of claim 1 which comprises 0.1% (w/v) of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline tartrate.
4 . The composition of either of claims 2 or 3 wherein said solution also comprises an SEC.
5 . The composition of claim 4 wherein said SEC comprises povidone.
6 . The composition of claim 4 wherein said SEC comprises polyvinyl alcohol.
7 . The composition of claim 4 wherein said SEC comprises an anionic polymer.
8 . The composition of claim 7 wherein said anionic polymer comprises a cellulose derivative.
9 . The composition of claim 8 wherein said anionic polymer comprises carboxymethylcellulose.
10 . The composition of claim 1 or 4 in which the composition further comprises a preservative.
11 . The composition of claim 10 in which said preservative is selected from the group consisting of a quaternary ammonium preservative, a oxidative preservative, and a biguanide preservative.
12 . The composition of claim 11 wherein the preservative is a quaternary ammonium preservative.
13 . The composition of claim 12 wherein the preservative is polyquaternium-1.
14 . The composition of claim 12 wherein the preservative is benzalkonium chloride.
15 . The composition of claim 12 wherein the preservative is cetrimide.
16 . The composition of claim 12 wherein the preservative is BDB.
17 . The composition of claim 11 in which the preservative is an oxidative preservative.
18 . The composition of claim 17 wherein the preservative is selected from the group consisting of an oxy-chloro and an oxy-borate preservative.
19 . The composition of claim 11 wherein the preservative comprises a biguanide preservative.
20 . The composition of claim 19 wherein the biguanide preservative comprises PHMB.
21 . A therapeutically effective aqueous ophthalmic composition comprising about 0.10% brimonidine tartrate and an oxi-chloro preservative at a pH of about 7.7.
22 . The composition of claim 21 further comprising a solubility enhancing component.
23 . The composition of claim 22 wherein the solubility enhancing component is selected from the group consisting of povidone, polyvinyl alcohol and carboxymethyl cellulose.
24 . A therapeutically effective aqueous ophthalmic composition comprising about 0.10% brimonidine tartrate and a quaternary ammonium preservative at a pH of about 7.7.
25 . The composition of claim 24 further comprising a solubility enhancing component.
26 . The composition of claim 25 wherein the solubility enhancing component is selected from the group consisting of povidone, polyvinyl alcohol and carboxymethyl cellulose.
27 . A therapeutically effective aqueous ophthalmic composition comprising about 0.10% brimonidine tartrate and a biguanide preservative at a pH of about 7.7.
28 . The composition of claim 27 further comprising a solubility enhancing component.
29 . The composition of claim 28 wherein the solubility enhancing component is selected from the group consisting of povidone, polyvinyl alcohol and carboxymethyl cellulose.